文献速递慢性肾脏病肾小球疾病

糖尿病大流行提示除「糖尿病肾病」外「糖尿病合并CKD」需求未满足——对临床前研究与药物测试的启示

The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该文质疑将糖尿病视为肾脏病主要病因的「糖尿病肾病」概念,认为多数进展至终末期肾病的2型糖尿病患者实为「糖尿病合并CKD」。作者指出,高血糖驱动的肾小球高滤过导致肾单位肥大,但蛋白尿出现较晚;而先前存在的CKD(肾单位数量少)在2型糖尿病发病前即存在,两者叠加加重单肾单位高滤过和肾小球肥大。仅基于高血糖的动物模型不能模拟此病理生理,建议采用肾单位消融的2型糖尿病动物模型并以GFR为主要终点。

要点

  • 「糖尿病肾病」概念可能不适用于多数进展至终末期肾病的2型糖尿病患者。
  • 先前存在的CKD(肾单位数量少)在2型糖尿病发病前即存在,与高血糖叠加加重肾损害。
  • 仅基于高血糖的动物模型不能模拟「糖尿病合并CKD」的病理生理。

核心结论

  • 「糖尿病肾病」概念可能不适用于多数进展至终末期肾病的2型糖尿病患者,应关注「糖尿病合并CKD」。
  • 仅基于高血糖的动物模型不能模拟目标患者群体的病理生理,预测临床试验结果能力差。

主要发现

  • 高血糖/钠-葡萄糖共转运蛋白2驱动的肾小球高滤过促进肾单位肥大,但单独作用可能十年后才出现蛋白尿。
  • 先前存在的CKD(如出生时肾单位数量少、肥胖、妊娠、肾脏老化或损伤相关肾单位丢失)通常在2型糖尿病发病前即存在。
  • 先前CKD与高血糖叠加进一步加重单肾单位高滤过和肾小球肥大,当滤过面积增大超过足细胞肥大能力时导致肾小球硬化和肾单位丢失。
  • 仅基于高血糖的「糖尿病肾病」动物模型不能模拟上述方面,因此难以预测通常在老年2型糖尿病合并CKD患者中进行的临床试验结果。

临床怎么用

  • 建议在2型糖尿病动物模型中采用肾单位消融以更好模拟目标患者群体「糖尿病合并CKD」的病理生理。
  • 建议以肾小球滤过率作为主要终点以更可靠地预测试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Curing 'diabetic nephropathy' is considered an unmet medical need of high priority. We propose to question the concept of 'diabetic nephropathy' that implies diabetes as the predominant cause of kidney disease, which may not apply to the majority of type 2 diabetics approaching end-stage kidney disease. With the onset of diabetes, hyperglycaemia/sodium-glucose co-transporter-2-driven glomerular hyperfiltration promotes nephron hypertrophy, which, however, on its own, causes proteinuria not before a decade later, probably because podocyte hypertrophy can usually accommodate an increase in the filtration surface. In contrast, precedent chronic kidney disease (CKD), that is, few nephrons per body mass, e.g. due to poor nephron endowment from birth, obesity, pregnancy, or renal ageing or injury-related nephron loss, usually precedes the onset of type 2 diabetes. This applies in particular in older adults, and each on its own, but especially in combination, further aggravates single nephron hyperfiltration and glomerular hypertrophy. Whenever this additional hyperglycaemia-driven enlargement of the glomerular filtration surface exceeds the capacity of podocytes for hypertrophy, podocytes detachment leads to glomerulosclerosis and nephron loss, i.e. CKD progression. Animal models of 'diabetic nephropathy' based only on hyperglycaemia do not mimic this aspect and therefore poorly predict outcomes of clinical trials usually performed on elderly CKD patients with type 2 diabetes. Thus, we advocate the use of renal mass (nephron) ablation in type 2 diabetic animals to better mimic the pathophysiology of 'CKD with diabetes' in the target patient population and the use of the glomerular filtration rate as a primary endpoint to more reliably predict trial outcomes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Anguiano Gómez L, Lei Y, Kumar Devarapu S, et al. The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing. Nephrol Dial Transplant. 2018. PMID: 28992221. doi:10.1093/ndt/gfx219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。